Wie können Basismedikamente die Gelenkdestruktion beeinflussen?

  • Manfred Schattenkirchner
Conference paper

Zusammenfassung

Die Frage nach den Mechanismen einer Destruktionshemmung durch Basismedika-mente bei der chronischen Polyarthritis setzt voraus, daß tatsächlich durch diese Medikamente aus klinischer Sicht Effekte erzielt werden, die einer grundlegenden Beeinflussung des Krankheitsverlaufes der chronischen Polyarthritis gleichkommen, wobei die progrediente Gelenkdestruktion als wesentliches Charakteristikum dieser Krankheit anzusehen ist. Die Antwort auf die erst durch solche Belege gerechtfertigte Frage ist spekulativ. Sie muß aussagen, auf welchem Wege erforschte Wirkungsmechanismen bekannter therapeutischer Substanzen mit den heute favorisierten Hypothesen der Pathogenese der chronischen Polyarthritis interferieren.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Calin A, Eiswood J, Klouda PT (1989) Destructive arthritis, rheumatoid factor and HLA-DR4. Susceptibility versus severity, a control case. Arthritis Rheum 32: 1221–1225PubMedCrossRefGoogle Scholar
  2. 2.
    Dixon Af, Davies J, Dormandy TL, Hamilton EBD, Holt PJL, Mason RM, Thompson M, Weber JCP, Zutshi DW (1975) Synthetic D-Penicillamine in rheumatoid arthritis. Double-blind controlled study of a high and low dosage regimen. Ann Rheum Dis 34: 416–421PubMedCrossRefGoogle Scholar
  3. 3.
    Feigenbaum SL, Masi AT, Kaplan SB (1979) Prognosis in rheumatoid arthritis: A longitudinal study of newly diagnosed younger adult persons. Am J Med 66: 377–384PubMedCrossRefGoogle Scholar
  4. 4.
    Freedman A, Steinberg VL (1960) Chloroquine in rheumatoid arthritis: A double-blindfold trial of treatment for one year. Ann Rheum Dis 19: 243PubMedCrossRefGoogle Scholar
  5. 5.
    Ghadially FN, Oryschak AF, Mitchell DM (1976) Ultrastructural changes produced in rheumatoid synovial membrane by chrysotherapy. Ann Rheum Dis 35: 67–72PubMedCrossRefGoogle Scholar
  6. 6.
    Gibson T, Huskisson EC, Wojtulewski JA (1976) Evidence that D-Penicillamine alters the course of rheumatoid arthritis. Rheumatol Rehabil 15: 211–215PubMedCrossRefGoogle Scholar
  7. 7.
    Gofton JP, O’Brien W (1983) Roentgenographic findings during auranofm treatment. Am J Med 75 [Suppl]: 142–144PubMedCrossRefGoogle Scholar
  8. 8.
    Hunneyball IM, Stewart GA, Stanworth DP (1978) The effects of oral D-Penicillamine treatment on experimental arthritis and associated immune response in rabbits. I Effect on humoral parameters. Immunology 34: 1053–1061Google Scholar
  9. 9.
    Hunneyball IM, Stewart GA, Stanworth DP (1978) The effect of oral D-Penicillamine treatment on experimental arthritis and associated immune response in rabbits. II The effects on cellular parameters. Immunology 35: 153–166Google Scholar
  10. 10.
    Hurvitz D, Hirschhorn K (1965) Suppression of in vitro lymphocyte responses by chloroquine. N Engl J Med 283: 23–26CrossRefGoogle Scholar
  11. 11.
    Larsen A, Dale K, Eek M, Pahle J (1983) Radiographic evaluation of rheumatoid arthritis by standard reference films. J Hand Surg 8: 667–669Google Scholar
  12. 12.
    Lipsky PE, Ugai K, Ziff M (1979) Alterations in human monocyte structure and functions induced by incubation with gold thiomalate. J Rheumatol [Suppl 5]: 130–136Google Scholar
  13. 13.
    Lipsky PE, Ziff M (1977) Inhibition of antigen- and mitogen-induced human T-lymphocyte proliferation by gold compounds. J Clin Invest 59: 455–466PubMedCrossRefGoogle Scholar
  14. 14.
    Multicentre Trial Group (1973) Controlled trial of D-Penicillamine in severe rheumatoid arthritis. Lancet 1: 275–280CrossRefGoogle Scholar
  15. 15.
    Rosenberg SA, Lipsky PE (1979) Monocyte dependence of pokeweed mitogen-induced differentiation of immunoglobulin secreting cells from human peripheral blood mononuclear cells. J Immunol 122: 926–931PubMedGoogle Scholar
  16. 16.
    Salmeron G, Lipsky PE (1982) Effect of gold compounds on human mononuclear phagocyte function. In: Schattenkirchner M, Müller W (ed) Modern Aspects of Gold Therapy. Rheumatology, An Annual Review. Karger, Basel, p 63–74Google Scholar
  17. 17.
    Salmeron G, Lipsky PE (1983) The immunosuppressive potential of antimalarials. Am J Med 75: 19–24PubMedCrossRefGoogle Scholar
  18. 18.
    Sharp JT, Lidsky MD, Duffy J (1982) Clinical responses during gold therapy for rheumatoid arthritis: Changes in synovitis, radiologically detectable erosive lesions, serum proteins and serologic abnormalities. Arthritis Rheum 25: 540–549Google Scholar
  19. 19.
    Sigler JW, Bluhm GB, Duncan H, Sharp JT, Ensign DC, McCrum WR (1974) Gold salts in the treatment of rheumatoid arthritis. A double-blind study. Ann Intern Med 80: 21–26Google Scholar
  20. 20.
    Sorenson JRJ (1976) Copper chelates as possible active forms of the antiarthritic agents. J Med Chem 19: 135–148PubMedCrossRefGoogle Scholar
  21. 21.
    Weis MW (1989) Corticosteroids in rheumatoid arthritis. Semin Arthr Rheum 19: 9–21CrossRefGoogle Scholar
  22. 22.
    Zvaifler NJ (1968) Antimalarial treatment of rheumatoid arthritis. Med Clin North Am 52: 759–764PubMedGoogle Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag, GmbH & Co. KG, Darmstadt 1990

Authors and Affiliations

  • Manfred Schattenkirchner
    • 1
    • 2
  1. 1.Rheuma-EinheitLudwig-Maximilians-Universität MünchenGermany
  2. 2.Rheuma-EinheitLudwig-Maximilians-Universität MünchenMünchen 2Germany

Personalised recommendations